Soluble CD40L and its role in essential hypertension: Diagnostic and therapeutic implications

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 8, Issue 3, 2008, Pages 194-202

  Ferroni, Patrizia ^a   Guadagni, Fiorella ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Hypertension; Inflammation; Platelet activation; Soluble CD40 ligand

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CD40 ANTIGEN; CD40 LIGAND; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN KINASE C; RAMIPRIL; VALSARTAN; BIOLOGICAL MARKER;

ANGIOGENESIS; BLEEDING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME PHOSPHORYLATION; ESSENTIAL HYPERTENSION; HUMAN; INFLAMMATION; LOW DRUG DOSE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLEIOTROPY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION; ANIMAL; BLOOD PRESSURE; ENDOTHELIUM CELL; HYPERTENSION; PATHOLOGY; PHYSIOLOGY; VASCULITIS;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CD40 LIGAND; ENDOTHELIAL CELLS; HUMANS; HYPERTENSION; RISK ASSESSMENT; THROMBOSIS; VASCULITIS;

EID: 54049125695     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152908785849125     Document Type: Review

References (120)

1. Granger, D.N.; Vowinkel, T.; Petnehazy, T. Modulation of the Inflammatory Response in Cardiovascular Disease. Hypertension, 2004, 43, 924-931.
2. Krieglstein, C.F.; Granger, D.N. Adhesion molecules and their role-in vascular disease. Am. J. Hypertens., 2001, 14, 44S-54S.
3. Stokes, K.Y.; Cooper, D.; Tailor A., Granger DN. Hypercholesterolemia promotes inflammation and microvascular dysfunction, role of nitric oxide and superoxide. Free Radic. Biol. Med., 2002, 33, 1026-1036.
4. Tailor A., Granger DN. Role of adhesion molecules in vascular regulation and damage. Curr. Hypertens. Rep., 2000, 2, 78-83.
5. Psaty, B.M.; Lumley, T.; Furberg C.D.; Schellenbaum, G.; Pahor, M.; Alderman, M.H.; Weiss, N.S. Health outcomes associated with various antihypertensive therapies used as first-line agents, a network meta-analysis. JAMA, 2003, 289, 2534-2544.
6. Brown, M.J. Better blood pressure control, how to combine drugs. J. Hum. Hypertens., 2003, 17, 81-86.
7. Taddei, S.; Solvetti, A. Endothelial dysfunction in essential hypertension, clinical implications. J. Hypertens., 2002, 20, 1671-1674.
8. Brunner, H.; Cockcroft, J.R.; Deanfield, J.; Donald, A.; Ferrannini, E.; Halcox, J.; Kiowski, W.; Luscher, T.F.; Mancia, G.; Natali, A.; Oliver, J.J.; Pessina, A.C.; Rizzoni, D.; Rossi, G.P.; Salvetti, A.; Spieker, L.E.; Taddei, S.; Webb, D.J. Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II, Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J. Hypertens., 2005, 23, 233-246.
9. Nadar, S.; Blann, A.D.; Lip, G.Y. Endothelial dysfunction, methods of assessment and application to hypertension. Curr. Pharm. Des., 2004, 10, 3591-3605.
10. Sciacqua, A.; Scozzafava, A.; Pujia, A.; Maio, R.; Borrello, F.; Andreozzi, F.; Vatrano, M.; Cassano, S.; Perticone, M.; Sesti, G.; Perticone, F. Interaction between vascular dysfunction and cardiac mass increases the risk of cardiovascular outcomes in essential hypertension. Eur. Heart J., 2005, 26, 921-927.
11. Zhou, M.S.; Schulman, I.H.; Raij, L. Nitric oxide., angiotensin II., and hypertension. Semin. Nephrol., 2004, 24, 366-378.
12. Landmesser, U.; Hornig, B.; Drexler, H Endothelial function, a critical determinant in atherosclerosis? Circulation, 2004, 109, II27-II33.
13. Pedrinelli, R.; Giampietro, O.; Carmassi, F.; Melillo, E.; Dell'Omo, G.; Catalano, G.; Matteucci, E.; Malarico, L.; Morale, M.; De Negri, F. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet, 1994, 344, 14-18.
14. Salazar, F.J.; Pinilla, J.M.; Lopez, F.; Romero, J.C.;Quesada, T. Renal effects of a prolonged synthesis inhibition of endothelium derived nitric oxide. Hypertension, 1992, 20, 113-117.
15. Felmeden, D.C.; Blann, A.D.; Spencer, C.G.; Beavers, D.G.; Lip, G.Y. A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension, relationship to cardiovascular risk and effects of treatment, a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul. Fibrinolysis, 2003, 14, 425-431.
16. Ferroni, P.; Basili, S.; Paoletti, V.; Davì, G. Endothelial dysfunction and oxidative stress in arterial hypertension. Nutr. Metab. Cardiovasc. Dis., 2006, 16, 222-233.
17. Cai, H.; Harrison, D.G. Endothelial dysfunction in cardiovascular diseases, the role of oxidant stress. Circulation Res., 2000, 87, 840-849.
18. Touyz, R.M. Reactive oxygen species., vascular oxidative stress., and redox signaling in hypertension, what is the clinical significance? Hypertension, 2004, 44, 248-252.
19. Redon, J.; Oliva, M.R.; Termos, C.; Giner, V.; Chaves, J.; Iradi, A.; Saez, G.T. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension, 2003, 41, 1096-1101.
20. Ward, N.C.; Hodgson, J.M.; Puddey, I.B.; Mori, T.A.; Beilin, L.J.; Croft, K.D. Oxidative stress in human hypertension, association with antihypertensive treatment., gender., nutrition., and lifestyle. Free Radic. Biol. Med., 2004, 36, 226-232.
21. Minuz, P.; Patrignani, P.; Gaino, S.; Seta, F.; Capone, M.L.; Tacconelli, S.; Degan, M.; Faccini, G.; Fornasiero, A.; Salamini, G.; Tommasoli, R.; Arosio, E.; Santonastaso, C.L.; Lechi, A.; Patrono, C. Determinants of platelet activation in human essential hypertension. Hypertension, 2004, 43, 64-70.
22. Touyz, R.M. Reactive oxygen species and angiotensin II signaling in vascular cells - implications in cardiovascular disease. Br. J. Med. Biol. Res., 2004, 37, 1263-1273.
23. Johansson, M.; Herlitz, H.; Jensen, G.; Rundqvist, B.; Friberg, P. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis, relation to sympathetic activation., renal function and treatment regimens. J. Hypertens., 1999, 17, 1743-1750.
24. Nickenig, G.; Harrison, D.G. The AT1-type angiotensin receptor in oxidative stress and atherogenesis., part I, oxidative stress and atherogenesis. Circulation, 2002, 105, 393-396.
25. Nickenig, G.; Harrison, D.G. The AT1-type angiotensin receptor in oxidative stress and atherogenesis., part II, AT1 receptor regulation. Circulation, 2002, 105, 530-536.
26. Touyz, R.M.; Schiffrin, E.L. Signal transduction mechanisms mediating the physiological and patho-physiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol. Rev., 2000, 52, 639-672.
27. de Gasparo, M. Angiotensin II and nitric oxide interaction. Heart Fail. Rev., 2002, 7, 347-358.
28. Touyz, R.M.; Chen, X.; He, G.; Quinn, M.T.; Schiffrin, E.L. Expression of a gp91phox-containing leukocyte-type NADPH oxidase in human vascular smooth muscle cells - modulation by Ang II. Circ. Res., 2002, 90, 1205-1213.
29. Cipollone, F.; Fazia, M.; Iezzi, A.; Pini, B.; Cuccurullo, C.; Zucchelli, M.; de Cesare, D.; Ucchino, S.; Spigonardo, F.; De Luca, M.; Muraro, R.; Bei, R.; Bucci, M.; Cuccurullo, F.; Mezzetti, A. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation, 2004, 109, 1482-1488.
30. Minuz, P.; Patrignani, P.; Gaino, S.; Degan, M.; Menapace, L.; Tommasoli, R.; Seta, F.; Capone, M.L.; Tacconelli, S.; Palatesi, S.; Bencini, C.; Del Vecchio, C.; Mansueto, G.; Arosio, E.; Santonastaso, C.L.; Lechi, A.; Moranti, A.; Patrono, C. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation, 2002, 106, 2800-2805.
31. Ruef, J.; Browatzki, M.; Pfeiffer, C.A.H.; Schmidt, J.; Kranzhöfer, R. Angiotensin II promotes the inflammatory response to CD40 ligation via TRAF-2. Vasc. Med., 2007, 12, 23-27.
32. Henn, V.; Slupsky, J.R.; Graefe, M.; Anagnostopoulos, I.; Foerster, R.; Mueller-Berghaus, G.; Kroczek, R.A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 1998, 391, 591-594.
33. Armitage, R.J.; Fanslow, W.C.; Strockbine, L.; Sato, T.A.; Clifford, K.N.; Macduff, B.M.; Anderson, D.M.; Gimpel, S.D.; Davis-Smith, T.; Maliszewski, C.R.; Clark, E.A.; Smith, C.A.; Grabstein, K.H.; Cosman, D.; Spriggs, M.K. Molecular and biological characterization of a murine ligand for CD40. Nature, 1992, 357, 80-82.
34. Graf, D.; Korthäuer, U.; Mages, H.W.; Senger, G.; Kroczek, R.A. Cloning of TRAP., a ligand for CD40 on human T cells, Eur. J. Immunol., 1992, 22, 3191-3194.
35. Lederman, S.; Yellin, M.J.; Krichevsky, A.; Belko, J.; Lee, J.J.; Chess, L. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J. Exp. Med., 1992, 175, 1091-1101.
36. Gauchat, J.F.; Henchoz, S.; Mazzei, G.; Aubry, J.P.; Brunner, T.; Blasey, H.; Life, P.; Talabot, D.; Flores-Romo, L.; Thompson, J.; Kishi, K.; Butterfield, J.; Dahinden, C.; Bonnefoy, J.Y. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature, 1993, 365, 340-343.
37. Andre, P.; Prasad, K.S.; Denis, C.V., Ming H.; Jessie M. P.; Richard O. H.; David R. P.; Denisa D. Wagner1CD40L stabilizes arterial tbrombi by a β3 integrin-dependent mechanism. Nat. Med., 2002, 8, 247-252.
38. Van Kooten, C.; Banchereau, J. CD40-CD40 ligand. J. Leukoc. Biol., 2000, 67, 2-17.
39. Inwald, D.P.; McDowall, A.; Peters, M.J.; Callard, R.E.; Klein, N.J. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ. Res., 2003, 92, 1041-1048.
40. Henn, V.; Steinbach, S.; Büchner, K.; Presek, P.; Kroczek, R.A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood, 2001, 98, 1047-1054.
41. Yellin, M.J.; Brett, J.; Baum, D.; Matsushima, A.; Szabolcs, M.; Stern, D.; Chess, L. Functional interactions of T cells with endothelial cells, the role of CD40L-CD40-mediated signals. J. Exp. Med., 1995, 182, 1857-1864.
42. Kiener, P.A.; Moran-Davis, P.; Rankin, B.M.; Wahl, A.F.; Aruffo, A.; Hollenbaugh, D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J. Immunol., 1995, 155, 4917-4925.
43. Mach, F.; Schönbeck, U.; Bonnefoy, J.Y.; Pober, J.S.; Libby, P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40, induction of collagenase., stromelysin., and tissue factor. Circulation, 1997, 96, 396-399.
44. Slupsky, J.R.; Kalbas, M.; Willuweit, A.; Henn, V.; Kroczek, R.A.; Müller-Berghaus, G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb. Haemost., 1998, 80, 1008-1014.
45. Thienel, U.; Loike, J.; Yellin, M.J. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol., 1999, 198, 87-95.
46. Karmann, K.; Hughes, C.C.; Schechner, J.; Fanslow, W.C.; Pober, J.S. CD40 on human endothelial cells, inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. USA, 1995, 92, 4342-4346.
47. Urbich, C.; Dernbach, E.; Aicher, A.; Zeiher, A.M.; Dimmeler, S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation, 2002, 106, 981-986.
48. Lee, J.R.; Koretzky, G.A. Production of reactive oxygen intermediates following CD40 ligation correlates with c-Jun N-terminal kinase activation and IL-6 secretion in murine B lymphocytes. Eur. J. Immunol., 1998, 28, 4188-4197.
49. Chakrabarti, S.; Varghese, S.; Vitseva, O.; Tanriverdi, K.; Freedman, J.E. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 2428-34.
50. Sanguigni, V.; Ferro, D.; Pignatelli, P.; Del Ben, M.; Nadia, T.; Saliola, M.; Sorge, R.; Violi, F. CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypereholesterolemia. J. Am. Coll. Cardiol., 2005, 45, 35-42.
51. Urbich, C.; Mallat; Z.; Tedgui, A.; Clauss, M.; Zeiher, A.M.; Dimmeler, S. Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J. Clin. Invest., 2001, 108, 1451-1458.
52. Davis, B.; Zou, M.H. CD40 ligand-dependent tyrosine nitration of prostacyclin synthase in vivo. Circulation, 2005, 112, 2184-2192.
53. Büchner, K.; Henn, V.; Gräfe, M.; de Boer, O.J.; Becker, A.E.; Kroczek, R.A. CD40 ligand is selectively expressed on CD4+ T cells and platelets, implications for CD40-CD40L signalling in atherosclerosis. J. Pathol., 2003, 201, 288-295.
54. Szabolcs, M.J.; Cannon, P.J.; Thienel, U.; Chen, L.; Michler, R.E.; Chess, L.; Yellin, M.J. Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease. Virchows Arch., 2000, 437, 149-159.
55. Melter, M.; Reinders, M.E.; Sho, M.; Pal, S.; Geehan, C.; Denton, M.D.; Mukhopadhyay, D.; Briscoe, D.M. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood, 2000, 96, 3801-3808.
56. Ferroni, P.; Santilli, F., Guadagni, F.; Basili, S.; Davì, G. Contribution of platelet-derived CD40 ligand to inflammation., thrombosis and neoangiogenesis. Curr. Med. Chem., 2007, 14, 2170-2180.
57. Krotz, F.; Sohn, H.Y.; Pohl, U. Reactive oxygen species, players in the platelet game. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1988-1996.
58. Freedman, J.E.; Keaney, J.F. Jr. Nitric oxide and superoxide detection in human platelets. Methods Enzymol., 1999, 301, 61-70.
59. Wachowicz, B.; Olas, B.; Zbikowska, H.M.; Buczynski, A. Generation of reactive oxygen species in blood platelets. Platelets., 2002, 13, 175-182.
60. Ferroni, P.; Basili, S.; Davì, G. Oxidant stress and platelet activation in hypercholesterolemia. Antiox. Redox. Signal., 2004, 6, 747-756.
61. Pignatelli, P.; Sanguigni, V.; Lenti, L.; Ferro, D.; Finocchi, A.; Rossi, P.; Violi, F. gp91phox-dependent expression of platelet CD40 ligand. Circulation, 2004, 110, 1326-1329.
62. Pignatelli, P.; Sanguigni, V.; Paola, S.G.; Lo Coco, E.; Lenti, L.; Violi, F. Vitamin C inhibits platelet expression of CD40 ligand. Free Radic. Biol. Med., 2005, 38, 1662-1666.
63. Nishimura, H.; Tsuji, H.; Masuda, H.; Nakagawa, K.; Nakahara, Y.; Kitamura, H.; Kasahara, T.; Sugano, T.; Yoshizumi, M.; Sawada, S.; Nakagawa, M. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb. Haemost., 1997, 77, 1189-1195.
64. Nishimura, H.; Tsuji, H.; Masuda, H.; Kasahara, T.; Yoshizumi, M.; Sugano, T.; Kimura, S.; Kawano, H.; Kunieda, Y.; Yano, S.; Nakagawa, K.; Kitamura, H.; Nakahara, Y.; Sawada, S.; Nakagawa, M. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells. Thromb. Haemost., 1999, 82, 1516-1521.
65. Larsson, P.T.; Schwieler, J.H.; Wallen, N.H. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul. Fibrinolysis., 2000, 11, 61-69.
66. Vaughan, D.E.; Lazos, S.A.; Tong, K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J. Clin. Invest., 1995, 95, 995-1001.
67. Ridker, P.M.; Gaboury, C.L.; Conlin, P.R.; Seely, E.W.; Williams, G.H.; Vaughan, D.E. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II, evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation, 1993, 87, 1969-1973.
68. Kerins, D.M.; Hao, Q.; Vaughan, D.E. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J. Clin. Invest., 1995, 96, 2515-2520.
69. Van Leeuwen, R.T.J.; Kol, A.; Andreotti, F.; Kluft, C.; Maseri, A.; Sperti, G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation, 1994, 90, 362-368.
70. Mogielnicki, A.; Chabielska, E.; Pawlak, R.; Szemraj, J.; Buczko, W. Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb. Haemost., 2005, 93, 1069-1076.
71. Basili, S.; Santilli, F.; Ferroni, P.; Davì, G. CD40/CD40L system and vascular disease. Intern. Emerg. Med., 2007, 2, 256-268.
72. Schonbeck, U.; Varo, N.; Libby, P.; Buring, J.; Ridker, P.M. Soluble CD40L and cardiovascular risk in women. Circulation, 2001, 104, 2266-2268.
73. Mo, V.Y.; De Lemos, J.A. Individualizing therapy in acute coronary syndromes, using a multiple biomarker approach for diagnosis., risk stratification., and guidance of therapy. Curr. Cardiol. Rep., 2004, 6, 273-278.
74. Yan, J.C.; Ma, G.S.; Wu, Z.G.; Kong, X.T.; Zong, R.Q.; Zhan, L.Z. Increased levels of CD40-CD40 ligand system in patients with essential hypertension. Clin. Chim. Acta, 2005, 355, 191-196.
75. Sonmez, A.; Dogru, T.; Yilmaz, MI.; Ocal, R.; Ozgurtas, T.; Kilic, S.; Eyileten, T.; Tasci, I.; Erbil, K.; Kocar, I.H. Soluble CD40 ligand levels in patients with hypertension. Clin. Exp. Hypertens., 2005, 27, 629-634.
76. Desideri, G.; Cipollone, F.; Valeri, L.; Grassi, D.; Necozione, S.; Croce, G.; Passacquale, G.; Garofalo, A.; Lippi, C.; Mezzetti, A.; Ferri, C. Enhanced plasma soluble CD40 ligand levels in essential hypertensive patients with blunted nocturnal blood pressure decrease. Am. J. Hypertens., 2007, 20, 70-76.
77. Alioglu, E.; Turk, U.O.; Bicak, F.; Tengiz, I.; Atila, D.; Barisik, V.; Ercan, E.; Akin, M. Vascular endothelial functions., carotid intima-media thickness., and soluble CD40 ligand levels in dipper and nondipper essential hypertensive patients. Clin. Res. Cardiol., 2008, DOI: 10.1007/s00392-008-0654-9.
78. Garg, J.P., Bakris, G.L. Microalbuminuria, marker of vascular dysfunction., risk factor for cardiovascular disease. Vasc. Med., 2002, 7, 35-43.
79. Jensen, J.S.; Feldt-Rasmussen, B.; Strandgaard, S.; Schroll, M.; Borch-Johnsen, K. Arterial hypertension., microalbuminuria., and risk of ischemic heart disease. Hypertension, 2000, 35, 898-903.
80. Jager, A.; Kostense, P.J.; Ruhé, H.G.; Heine, R.J.; Nijpels, G.; Dekker, J.M.; Bouter, L.M.; Stehouwer, C.D. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality., especially among hypertensive subjects, five-year follow-up of the Hoorn Study. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 617-624.
81. Tsioufis, C.; Dimitriadis, K.; Taxiarchou, E.; Vasiliadou, C.; Chartzoulakis, G.; Tousoulis, D.; Manolis, A.; Stefanadis, C.; Kallikazaros, I. Diverse associations of microalbuminuria with C-reactive protein., interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am. J. Hypertens., 2006, 19, 462-466.
82. Bautista L.E. Associations of microalbuminuria with inflammation markers in hypertensive men. Am. J. Hypertens., 2006, 19, 467.
83. Ferroni, P.; Guagnano, M.T.; Falco, A.; Paletti, V.; Manigrasso, M.R.; Michetti, N.; Santilli, F.; Guadagni, F.; Basili, S.; Davì, G. Association of low-grade inflammation and platelet activation in hypertensive patients with microalbuminuria. Clin. Sci., 2008, 114, 449-455.
84. Ferroni, P.; Martini, F.; D'Alessandro, R.; Magnapera, A.; Raparelli, V.; Scarno, A.; Davì, G.; Basili, S.; Guadagni, F. In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients. Clin. Chim. Acta, 2008, 388, 33-37.
85. Patel, J.V.; Lim, H.S.; Nadar, S.; Tayebjee, M.; Hughes, E.A.; Lip, G.Y. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension, relationship to indices of angiogenesis. J. Hypertens., 2006, 24, 117-121.
86. Blann, A.D.; Nadar, S.K.; Lip, G.Y. The adhesion molecule P-selectin and cardiovascular disease. Eur. Heart J., 2003, 24, 2166-2179.
87. Andre, P. P-selectin in haemostasis. Br. J. Haermatol., 2004, 126, 298-306.
88. Davì, G.; Romano, M.; Mezzetti, A.; Procopio, A.; Iacobelli, S.; Antidormi, T.; Bucciarelli, T.; Alessandrini, P.; Cuccurullo, F.; Bittolo Bon, G. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation, 1998, 97, 953-957.
89. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens., 2007, 25, 1105-1187.
90. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.; Shahinfar, S. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 2001, 345, 861-869.
91. Dahlof, B.; Devereux, R.B.; Kjeldsen, S.E.; Julius, S.; Beevers, G.; de Faire, U.; Fyhrquist, F.; Ibsen, H.; Kristiansson, K.; Lederballe-Pedersen, O.; Lindholm, L.H.; Nieminen, M.S.; Omvik, P.; Oparil, S.; Wedel, H. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE), a randomised trial against atenolol. Lancet, 2002, 359, 995-1003.
92. Cohn, J.N.; Tognoni, G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med., 2001, 343, 1667-7165.
93. Pfeffer, M.A.; McMurray, J.J.V.; Velazquez, E.J.; Rouleau, J.L.; Køber, L.; Maggioni, A.P.; Solomon, S.D.; Swedberg, K.; Van de Werf, F.; White, H.; Leimberger, J.D.; Henis, M.; Edwards, S.; Zelenkofske, S.; Sellers, M.A.; Califf, R.M. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan., captopril., or both in myocardial infarction complicated by heart failure., left ventricular dysfunction., or both. N. Engl. J. Med., 2003, 349, 1893-1906.
94. Lewis, E.J.; Hunsicker, L.G.; Clarke, W.R.; Berl, T.; Pohl, M.A.; Lewis, J.B.; Ritz, E.; Atkins, R.C.; Rohde, R.; Raz, I., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001, 345, 851-860.
95. Granger, C.B.; McMurray, J.J.V.; Yusuf, S.; Held, P.; Michelson, E.L.; Olofsson, B.; Ostergren, J.; Pfeffer, M.A.; Swedberg, K. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors, the CHARM-Alternative trial. Lancet, 2003, 362, 772-776.
96. Koh, K.K.; Quon, M.J.; Han, S.H.; Chung, W.J.; Ahn, J.Y.; Seo, Y.H.; Kang, M.H.; Ahn, T.H., Choi, I.S.; Shin, E.K. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic., hypertensive patients. Circulation, 2004, 110, 3687-3692.
97. Han, S.H.; Koh, K.K.; Quon, M.J.; Lee, Y.; Shin, E.K. The effects of simvastatin., losartan., and combined therapy on soluble CD40 ligand in hypercholesterolemic., hypertensive patients. Atherosclerosis, 2007, 190, 205-211.
98. Koh, K.K.; Quon, M.J.; Han, S.H.; Chung, W.J.; Ahn, J.Y.; Kim, J.A.; Lee, Y.; Shin, E.K. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care, 2006, 29, 195-201.
99. Koh, K.K.; Quon, M.J.; Han, S.H.; Chung, W.J.; Lee, Y.; Shin, E.K. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int. J. Cardiol., 2006, 108 96-100.
100. Siebers, M.J.; Goodfriend, T.L. Platelet angiotensin receptors in young and old humans. J. Gerontol., 1986, 41, 574-578.
101. Pawlak, M.; Macdonald, G. Platelet angiotensin II receptors in pregnancy. Clin. Sci. (Lond)., 1992, 83, 737.
102. Graves, S.W.; Moore, T.J.; Seely, E.W. Increased platelet angiotensin II receptor number in pregnancy-induced hypertension. Hypertension, 1992, 20, 627-632.
103. Baker, P.N.; Broughton Pipkin, F.; Symonds, E.M. Platelet angiotensin II binding sites in hypertension in pregnancy. Lancet, 1989, 2, 1151.
104. Kalinowski, L.; Matys, T.; Chabielska, E.; Buczko, W.; Malinski, T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension, 2002, 40, 521-527.
105. Leu, H.B.; Charng, M.J.; Ding, P.Y. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure., platelets., and endothelium function in patients with essential hypertension. Jpn. Heart J. 2004, 45, 623-635.
106. Serebruany, V.L.; Malinin, A.I.; Lowry, D.R.; Sane, D.C.; Webb, R.L.; Gottlieb, S.O.; O'Connor, C.M.; Hennekens, C.H. Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan, a possible missing link to explain benefits of angiotensin II receptor blockers in patients after acute vascular events. J. Cardiovasc. Pharmacol., 2004, 43, 677-684.
107. Petnehazy, T.; Stokes, K.Y.; Russell, J.M.; Granger, D.N. Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules. Hypertension, 2005, 45, 209-215.
108. Utsugisawa, K.; Kizawa, H.; Nagane, Y.; Kondoh, R.; Iwa, Y.; Akutsu, H.; Tohgi, H.; Terayama, Y. Biphasic effects of angiotensin II and receptor antagonism on aggregability and protein kinase C phosphorylation in human platelets. Thromb. Haemost., 2005, 94, 1012-1018.
109. Grothusen, C.; Umbreen, S.; Konrad, I.; Stellos, K.; Schulz, C.; Schmidt, B.; Kremmer, E.; Teebken, O.; Massberg, S.; Luchtefeld, M.; Schieffer, B.; Gawaz, M. EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism, potential impact on atherothrombosis. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 1184-1190.
110. Serebruany, V.L.; Pokov, A.N.; Malinin, A.I.; O'Connor, C.; Bhatt, D.L.; Tanguay, J.F.; Sane, D.C.; Hennekens, C.H. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives, Valsartan Inhibits Platelets (VIP) trial. Am. Heart J., 2006, 151, 92-99.
111. Koh, K.K.; Quon, M.J.; Han, S.H.; Ahna, J.Y.; Lee, Y.; Shin, E.K. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1 + 2 in patients with type 2 diabetes. Atherosclerosis, 2007, 194 230-237.
112. Brili, S.; Tousoulis, D.; Antoniades, C.; Vasiliadou, C.; Karali, M.; Papageorgiou, N.; Ioakeimidis, N.; Marinou, K.; Stefanadi, E.; Stefanadis, C. Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta, a randomized cross-over study. J. Am. Coll. Cardiol., 2008 19, 51, 742-749.
113. Blann, A.D.; Nadar, S.; Lip, G.Y.H. Pharmacological Modulation of Platelet Function in Hypertension. Hypertension, 2003, 42, 1-7.
114. de Champlain, J. Do angiotensin II antagonists provide benefits beyond blood pressure reduction? Adv. Ther., 2005, 22, 117-136.
115. Asmar, R. Targeting effective blood pressure control with angiotensin receptor blockers. Int. J. Clin. Pract., 2006, 60, 315-320.
116. Brown, M.J. Better blood pressure control: how to combine drugs. J. Hum. Hypertens., 2003, 17, 81-86.
117. Nannizzi-Alaimo, L.; Alves, V.L.; Phillips, D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation, 2003, 107, 1123-1128.
118. Pignatelli, P.; Cangemi, R.; Celestini, A.; Carnevale, R.; Polimeni, L.; Martini, A.; Ferro, D.; Loffredo, L.; Violi, F. Tumour necrosis factor {alpha} upregulates platelet CD40L in patients with heart failure. Cardiovasc. Res., 2008, 78, 515-522.
119. Santilli, F.; Davì, G.; Consoli, A.; Cipollone, F.; Mezzetti, A.; Falco, A.; Taraborelli, T.; Devangelio, E.; Ciabattoni, G.; Basili, S.; Patrono, C. Thromboxane dependent CD40 ligand release in type 2 diabetes mellitus. J. Am. Coll. Cardiol., 2006, 47, 391-397.
120. Ferroni, P.; Basili, S.; Davì, G. Platelet activation, inflammatory mediators and hypercholesterolemia. Curr. Vasc. Pharmacol., 2003, 1, 157-169.